RNA-seq and integrated network analysis reveals the hub genes and key pathway of paclitaxel inhibition on Adriamycin resistant diffuse large B cell lymphoma cells

About 40% of patients with diffuse large B-cell lymphoma (DLBCL) develop drug resistance after first-line chemotherapy, which remains a major cause of morbidity and mortality. The emergence of DLBCL drug resistance is mainly related to Adriamycin. Our previous research shows that Paclitaxel could be...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Haoyuan, Luo, Bin, Qin, Yingying, Li, Sizhu, Peng, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973673/
https://www.ncbi.nlm.nih.gov/pubmed/35263200
http://dx.doi.org/10.1080/21655979.2022.2048772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973673/
https://www.ncbi.nlm.nih.gov/pubmed/35263200
http://dx.doi.org/10.1080/21655979.2022.2048772

Ejemplares similares